Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arthroplasty Specimen Evaluation in Phase 3 Fasinumab Osteoarthritis Program
2018-001618-13Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fasinumab in knee osteoarthritis (OA), hip osteoarthritis and osteoarthritis (OA) (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Descriptive histological evaluation of synovium, Descriptive histological evaluation of cartilage and 1 more. Started Sep 2018; status: terminated.
02
Drugs
fasinumab
03
Conditions
knee osteoarthritis (OA)hip osteoarthritisosteoarthritis (OA)
Beyond the preview
Go deeper on 2018-001618-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001618-13.